In this way, it was demonstrated that IFN-β treatment in RRMS patients could significantly upregulate the expression of CD40 on monocytes compared to untreated patients, reinforcing monocyte responsiveness in the release of neuroprotective factor BDNF via CD40 stimulation [202]. Here, CD40 is linked to relapsing-remitting multiple sclerosis.